 |
市场调查报告书
商品编码
1518500
羟考酮药物市场 - 按产品类型（短效、长效羟考酮）、剂型（片剂、胶囊）、适应症（神经性疼痛、癌症疼痛）、配销通路（医院药房、线上药局） - 全球预测2024 - 2032Oxycodone Drugs Market - By Product Type (Short-acting, Long-acting Oxycodone), Dosage Form (Tablets, Capsules), Indication (Neuropathic Pain, Cancer Pain), Distribution Channel (Hospital Pharmacies, Online Pharmacies) - Global Forecast 2024 - 2032 |
||||||
由于羟考酮药物在老龄化人口疼痛管理中的作用日益增强，预计 2024 年至 2032 年，羟考酮药物市场规模的复合年增长率将达到 5.7%。医疗保健提供者正在仔细处方这些药物，以减轻老年患者的慢性疼痛。
随着人口老化的扩大，人们越来越重视监测和管理鸦片类药物的使用，以减轻依赖和滥用的风险。据世界卫生组织称，到2050年，全球60岁及以上人口将增加一倍，达到21亿。医疗专业人员正在关注替代性疼痛管理策略，例如非鸦片类药物和疗法。正在进行的研发工作也在针对老年人的具体需求创造更安全、更有效的治疗方法，以确保疼痛管理获得更好的长期结果。
整个羟考酮药物市场分为药物类型、剂型、适应症、配销通路和地区。
就剂型而言，注射剂领域预计从 2024 年至 2032 年将录得显着的复合年增长率。医疗专业人员正在进行这些注射，以确保有效控制疼痛，尤其是在急性护理环境中。随着慢性疼痛发病率的增加，医疗保健提供者正在优化羟考酮注射方案，以尽量减少副作用和依赖性风险。
从配销通路来看，由于需要疼痛管理的患者可以轻鬆获得多种药物，在线药房领域的羟考酮药品行业预计将从 2024 年到 2032 年增长。线上平台在确保个人（尤其是行动不便的人）能够方便地获得药物方面发挥着至关重要的作用。这些药局也实施严格的验证流程，以加强安全措施，防止误用并确保正确配药。
从地区来看，在医疗基础设施发展和医疗支出不断增加的推动下，亚太地区羟考酮药物市场规模预计将在 2024 年至 2032 年间呈现强劲增长。亚太地区的政府和私营部门正在投资现代化医疗设施并扩大获得疼痛管理治疗的机会。为提高羟考酮的品质和可用性而进行的持续投资，以确保整个地区的患者获得有效且规范的疼痛缓解，也将推动该产品的使用。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 慢性疼痛盛行率增加
- 创伤和手术事件增加
- 老年人口增加
- 药物输送系统的进展
- 产业陷阱与挑战
- 监管限制
- 替代疼痛管理技术
- 成长动力
- 成长潜力分析
- 监管环境
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按药物类型，2021 - 2032
- 主要趋势
- 短效羟考酮
- 长效羟考酮
第 6 章：市场估计与预测：按剂型，2021 - 2032
- 主要趋势
- 平板电脑
- 胶囊
- 注射
第 7 章：市场估计与预测：按指标划分，2021 - 2032 年
- 主要趋势
- 神经性疼痛
- 肌肉骨骼疼痛
- 癌症痛
- 术后疼痛
- 其他适应症
第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年
- 主要趋势
- 医院药房
- 药局和零售药局
- 网路药局
第 9 章：市场估计与预测：按地区划分，2021 - 2032 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
- 亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
第 10 章：公司简介
- Alvogen
- Ani Pharmaceutical Inc.
- Daiichi Sankyo Company Ltd.
- Endo Pharmaceuticals
- Mallinckrodt Pharmaceuticals
- Mylan N.V.
- Protega Pharmaceuticals LLC
- Purdue Pharma LP
- Quagen Pharma
- Teva Pharmaceuticals, Inc.
Oxycodone Drugs Market size is projected to record 5.7% CAGR from 2024 to 2032, driven by their growing role in pain management for the aging population. Healthcare providers are carefully prescribing these medications to alleviate chronic pain in elderly patients.
With the expansion of the aging population, there is growing emphasis on monitoring and managing opioid use to mitigate risks of dependency and misuse. According to WHO, by 2050, the world's population of people aged 60 years and older will double to 2.1 billion. Medical professionals are focusing on alternative pain management strategies, such as non-opioid medications and therapies. The ongoing R&D efforts are also creating safer and more effective treatments tailored to the specific needs of older adults for ensuring better long-term outcomes for pain management.
The overall oxycodone drugs market is segregated into drug type, dosage form, indication, distribution channel, and region.
In terms of dosage form, the injections segment is expected to record significant CAGR from 2024 to 2032. Oxycodone injections are used for managing severe pain in patients who require immediate relief. Medical professionals are administering these injections to ensure effective pain control especially in acute care settings. As the incidence of chronic pain increases, healthcare providers are optimizing oxycodone injection protocols to minimize side effects and dependency risks.
By distribution channel, the oxycodone drugs industry from the online pharmacies segment is projected to rise from 2024 to 2032, driven by the easy access to multiple drugs for patients in need of pain management. Online platforms play a crucial role in ensuring that individuals particularly those with mobility issues and can obtain their medications conveniently. These pharmacies are also implementing strict verification processes for enhancing security measures to prevent misuse and ensure proper dispensing.
Regionally, the Asia Pacific oxycodone drugs market size is projected to exhibit robust growth between 2024 and 2032, fueled by increasing healthcare infrastructure development and escalating healthcare expenditure. Governments and private sectors in APAC are investing on modernizing healthcare facilities and expanding access to pain management treatments. The ongoing investments for enhancing the quality and availability of oxycodone for ensuring that patients receive effective and regulated pain relief across the region will also push the product uptake.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increase in the prevalence of chronic pain
- 3.2.1.2 Increase in incident of trauma and surgeries
- 3.2.1.3 Rise in geriatric population
- 3.2.1.4 Advancement in drug delivery system
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Regulatory restrictions
- 3.2.2.2 Alternative pain management technologies
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Short-acting oxycodone
- 5.3 Long-acting oxycodone
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Tablets
- 6.3 Capsules
- 6.4 Injections
Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Neuropathic pain
- 7.3 Musculoskeletal pain
- 7.4 Cancer pain
- 7.5 Post-operative pain
- 7.6 Other indications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Drug stores & retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Alvogen
- 10.2 Ani Pharmaceutical Inc.
- 10.3 Daiichi Sankyo Company Ltd.
- 10.4 Endo Pharmaceuticals
- 10.5 Mallinckrodt Pharmaceuticals
- 10.6 Mylan N.V.
- 10.7 Protega Pharmaceuticals LLC
- 10.8 Purdue Pharma LP
- 10.9 Quagen Pharma
- 10.10 Teva Pharmaceuticals, Inc.
